Sleep Problems in Children with Attention Deficit/Hyperactivity Disorder: Current Status of Knowledge and Appropriate Management
- 2.2k Downloads
Attention deficit hyperactivity disorder (ADHD) affects approximately 5 % of children and adolescents, and sleep problems are common in these patients. There is growing evidence informing the significant importance of sleep problems in youth with ADHD. The sleep problems in children with ADHD include specific sleep disorders and sleep disturbances due to comorbid psychiatric disorders or ADHD medications. The specific sleep disorders of ADHD children include behaviorally based insomnia, sleep-disordered breathing, and restless legs syndrome/periodic limb movement disorder. Current practices on the management of sleep problems for ADHD children are based mostly on expert consensus, whereas more evidence-based literature can be found only recently. Assessment of the sleep conditions in ADHD children before initiation of pharmacotherapy is the currently recommended guideline, and good sleep hygiene can be considered as the first-line treatment option. In addition to modifying the dose regimens, formulation, or alternative stimulants when sleep problems are encountered in ADHD children, atomoxetine, once daily guanfacine extended release, and melatonin are potential choices for ADHD children with more severe sleep problems. In this review, we aimed to provide the most updated information, preferably based on meta-analyses, systemic review, and randomized controlled trials published in the latest 3 years, in order to be clinically useful for practitioners and clinicians.
KeywordsSleep disorders Attention deficit hyperactivity disorder Children Melatonin Insomnia
This material is the result of work supported with resources and the use of facilities at the Yunlin Chang Gung Memorial Hospital, Yunlin, Taiwan, Republic of China.
Compliance with Ethical Standards
Conflict of Interest
Ming-Horng Tsai, Jen-Fu Hsu, and Yu-Shu Huang declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance
- 2.•Um YH, Jeong JH, Hong SC, Kim TW, Lim HK, Seo HJ, et al. Association between sleep parameters and cognitive function in drug-naïve children with attention-deficit hyperactivity disorder: a polysomnographic study. Sleep Med. doi: 10.1016/j.sleep.2015.11.016. This study documented the relationship between sleep parameters and cognitive function in drug-naïve children with ADHD, while most subjects in previous studies were on medication, which is a potent confounding factor.
- 5.Becker SP, Pfiffner LJ, Stein MA, Burns GL, McBurnett K. Sleep habits in children with attention-deficit/hyperactivity disorder predominantly inattentive type and associations with comorbid psychopathology symptoms. Sleep Med. 2015;11:S1389–9457.Google Scholar
- 6.Canals J, Morales-Hidalgo P, Jané MC, Domènech E. ADHD prevalence in Spanish preschoolers: comorbidity, socio-demographic factors, and functional consequences. J Atten Disord. 2016. doi: 10.1177/1087054716638511.
- 10.van Lieshout M, Luman M, Twisk JW, van Ewijk H, Groenman AP, Thissen AJ, et al. A 6-year follow-up of a large European cohort of children with attention-deficity/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood. Eur Child Adolesc Psychiatry. 2016. doi: 10.1007/s00787-016-0820-y.
- 11.Casas M, Rösler M, Sandra Kooij JJ, Ginsberg Y, Ramos-Quiroga JA, Heger S, et al. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. World J Biol Psychiatry. 2013;14:268–81.PubMedCrossRefGoogle Scholar
- 12.Rönnlund H, Elovainio M, Virtanen I, Matomäki J, Lapinleimu H. Poor parental sleep and the reported sleep quality of their children. Pediatrics. 2016. doi: 10.1542/peds.2015-3425.
- 18.Mitchison GM, Njardvik U. Prevalence and gender differences of ODD, anxiety, and depression in a sample of children with ADHD. J Atten Disord. 2015. doi: 10.1177/1087054715608442.
- 22.•Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant medications and sleep for youth with ADHD: a meta-analysis. Pediatrics. 2015;136:1144–53. This is a recent published meta-analysis of stimulant medication regarding its effects of longer sleep latency, worse sleep efficiency, and shorter sleep duration.PubMedCrossRefGoogle Scholar
- 28.••Hiscock H, Sciberras E, Mensah F, Gerner B, Efron D, Khano S, et al. Impact of a behavioral sleep intervention on symptoms and sleep in children with attention-deficit/hyperactivity disorder, and parental mental health: randomized controlled trial. BMJ. 2015;350:h68. This study providing evidence-based information using RCT documenting the effect of behavior sleep intervention on ADHD children with sleep problems.PubMedPubMedCentralCrossRefGoogle Scholar
- 29.••Vidal R, Castells J, Richarte V, Palomar G, Garcia M, Nicolau R, et al. Group therapy for adolescents with attention-deficit/hyperactivity disorder: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54:275–82. This study is the latest and an important RCT documenting the effect of group therapy for adolescents with ADHD.PubMedCrossRefGoogle Scholar
- 30.•Santisteban JA, Stein MA, Bergmame L, Gruber R. Effect of extended-release dexmethylphenidate and mixed amphetamine salts on sleep: a double-blind, randomized, crossover study in youth with attention-deficit hyperactivity disorder. CNS Drugs. 2014;28:825–33. This study highlights that higher stimulant doses are associated with reduced sleep duration and later sleep start times, regardless of medication class.PubMedPubMedCentralCrossRefGoogle Scholar
- 34.Dalsgaard S, Nielsen HS, Simonsen M. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study. J Child Adolesc Psychopharmacol. 2013;23:432–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 45.Sedky K, Carvalho K, Lippmann S. Attention deficit hyperactivity disorder and sleep disordered breathing in children. J Pediatr Biochem. 2013;3:61–7.Google Scholar
- 47.•Amiri S, AbdollahiFakhim S, Lotfi A, Bayazian G, Sohrabpour M, Hemmatjoo T. Effect of adenotonsillectomy on ADHD symptoms of children with adenotonsillar hypertrophy and sleep disordered breathing. Int J Pediatr Otorhinolaryngol. 2015;79:1213–7. This study documented the significant effect of adenotonsillectomy on ADHD children with sleep disordered breathing.PubMedCrossRefGoogle Scholar
- 49.•Song SA, Tolisano AM, Cable BB, Camacho M. Neurocognitive outcomes after pediatric adenotonsillectomy for obstructive sleep apnea: a systemic review and meta-analysis. Int J Pediatr Otorhinolaryngol. 2016;83:205–10. This study documented the significant effect of adenotonsillectomy on obstructive sleep apnea, which leads to improved neurocognitive outcomes.PubMedCrossRefGoogle Scholar
- 60.•Trenkwalder C, Allen R, Högl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016;86:1336–43. This article provides the latest updated information regarding restless legs syndrome being as a continuous spectrum with a major genetic contribution and a major comorbid disease of other entities.PubMedCrossRefGoogle Scholar
- 67.England SJ, Picchietti DL, Couvadelli BV, Fisher BC, Siddigui F, Wagner ML, et al. L-Dopa improves restless legs syndrome and periodic limb movements in sleep but not attention-deficit/hyperactivity disorder in a double-blind trial in children. Sleep Med. 2011;12:471–7.PubMedPubMedCentralCrossRefGoogle Scholar
- 72.Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the international restless legs syndrome study group. Sleep Med. 2013;14:675–84.PubMedCrossRefGoogle Scholar
- 73.Cuffe SP, Visser SN, Holbrook JR, Danielson ML, Geryk LL, Wolraich ML, et al. ADHD and psychiatric comorbidity: functional outcomes in a school-based sample of children. J Atten Disord. 2015. doi: 10.1177/1087054715613437.
- 74.•Becker SP, Langberg JM, Evans SW. Sleep problems predict comorbid externalizing behaviors and depression in young adolescents with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2015;24:897–907. This article highlights the importance of sleep problems as the important predictor of externalizing behavior and depression in ADHD adolescents.PubMedCrossRefGoogle Scholar
- 75.•Shanahan L, Copeland WE, Angold A, Bondy CL, Costello EJ. Sleep problems predict and are predicted by generalized anxiety/depression and oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2014;53:550–8. This is the first study documenting sleep problems can predict and be predicted by generalized anxiety/depression and oppositional defiant disorder.PubMedPubMedCentralCrossRefGoogle Scholar
- 76.•Cortese S, Brown TE, Corkum P, Gruber R, O’Brien LM, Stein M, et al. Assessment and management of sleep problems in youths with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2013;52:784–96. This is the expert consensus and meta-analysis regarding the latest assessment and management of sleep problems in youths with ADHD.PubMedCrossRefGoogle Scholar
- 77.Papadopoulos N, Sciberras E, Hiscock H, Mulraney M, McGillivray J, Rinehart N. The efficacy of a brief behavioral sleep intervention in school-aged children with ADHD and comorbid autism spectrum disorder. J Atten Disord. 2015. doi: 10.1177/1087054714568565.
- 78.Sciberras E, Mulraney M, AndersonV, Rapee RM, Nicholson JM, Efron D, et al. Managing anxiety in children with ADHD using cognitive-behavioral therapy: a pilot randomized controlled trial. J Atten Disord. 2015. doi: 10.1177/1087054715584054.
- 79.••Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015;11:CD009885. This is the latest systemic review and meta-analysis regarding the stimulant effects on children with ADHD.PubMedGoogle Scholar
- 80.•Storebø OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systemic review with meta-analyses and trial sequential analyses of randomized clinical trials. BMJ. 2015;351:h5203. This study focusing on whether methylphenidate beneficial or harmful for treatment of ADHD children concludes caution regarding the use of methylphenidate, since it is associated with an increased risk of non-serious adverse events. Google Scholar
- 82.Becker SP, Froehlich TE, Epstein JN. Effects of methylphenidate on sleep functioning in children with attention-deficit/hyperactivity disorder. J Dev Behav Pediatr. 2016;37(5):395–404.Google Scholar
- 83.Wang LJ, Chen CK, Huang YS. Gender differences in the behavioral symptoms and neuropsychological performance of patients with attention-deficit/hyperactivity disorder treated with methylphenidate: a two-year follow-up study. J Child Adolesc Psychopharmacol. 2015;25:501–8.PubMedCrossRefGoogle Scholar
- 87.Coghill DR, Banaschewski T, Lecendreux M, Soutullo C, Zuddas A, Adeyi B, et al. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. Neuropsychiatr Dis Treat. 2014;10:2039–47.PubMedPubMedCentralGoogle Scholar
- 88.Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, et al. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry. 2013;54:527–35.PubMedCrossRefGoogle Scholar
- 92.•Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, et al. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs. 2014;28:1059–69. This study compared the efficacy and side effects of lisdexamfetamine dimesylate and atomoxetine in children with ADHD.PubMedPubMedCentralCrossRefGoogle Scholar
- 93.Warrer P, Thomsen PH, Dalsgaard S, Hansen EH, Aagaard L, Wallach Kildemoes H, et al. Switch in therapy from methylphenidate to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: an analysis of patient records. J Child Adolesc Psychopharmacol. 2016;26(4):354–61.Google Scholar
- 95.•Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53:174–87. This study using meta-analysis documented the efficacy and safety of atomoxetine, and concluded it as the alternative choice for children and adolescents with ADHD.PubMedCrossRefGoogle Scholar
- 96.Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24:1861–72.PubMedCrossRefGoogle Scholar
- 97.•Stein MA, Sikirica V, Weiss MD, Robertson B, Lyne A, Newcorn JH. Does guanfacine extended release impact functional impairment in children with attention-deficit/hyperactivity disorder? Results from a randomized controlled trial. CNS Drugs. 2015;29:953–62. This updated RCT documented guanfacine extended release treatment is associated with reductions in ADHD symptoms, and has tolerable adverse events.PubMedPubMedCentralCrossRefGoogle Scholar
- 98.Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081–92.PubMedPubMedCentralCrossRefGoogle Scholar
- 104.Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Dittmann RW, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227–46.PubMedCrossRefGoogle Scholar
- 108.Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52:921–30.PubMedCrossRefGoogle Scholar
- 113.Mohammadi MR, Mostafavi SA, Keshavarz SA, Eshraghian MR, Hosseinzadeh P, Hosseinzadeh-Attar MJ, et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iran J Psychiatry. 2012;7:87–92.PubMedPubMedCentralGoogle Scholar